Research out in this week's issue of JAMA confirms the success of a treatment for persistent atrial fibrillation (AFib) that combines the standard treatment, catheter ablation, with a separate infusion of ethanol, or alcohol, to the vein of Marshall.
Researchers involved in the phase II NRG Oncology RTOG 0526 trial studying low dose rate (LDR) prostate brachytherapy (BT) following local recurrence (LR) after external beam radiotherapy (EBRT) for patients with low-to-intermediate risk prostate cancer reported late Grade 3 gastrointestinal and genitourinary adverse events (AEs) occurring in 14% of trial participants.
A genetic analysis of non-small cell lung cancer (NSCLC) patients on the phase III NRG Oncology RTOG 0617 clinical trial assessing radiation dose discovered that high dose radiation therapy is associated with shorter survival times among patients with a radiation-sensitive genotype in DNA repair pathway. These findings were presented at the virtual edition of the American Society for Radiation Oncology's (ASTRO) Annual Meeting in October 2020.
A tiny device the size of a small paperclip has been shown to help patients with upper limb paralysis to text, email and even shop online in the first human trial.
Researchers demonstrated the success of a fully implantable wireless medical device, the Stentrode™ brain-computer interface (BCI), designed to allow patients with severe paralysis to resume daily tasks -- including texting, emailing, shopping and banking online -- without the need for open brain surgery. The first-in-human study was published in the (i>Journal of NeuroInterventional Surgery™, the leading international peer-reviewed journal for the clinical field of neurointerventional surgery.
The first results of the COVID-19 Genetics Host Initiative were presented at the ASHG 2020 Annual Meeting.
According to an open-access article in ARRS' American Journal of Roentgenology, fluorine-18-labeled fluciclovine PET/MRI demonstrated utility in the initial staging of high-risk prostate cancer, as well as for evaluating the response to androgen deprivation therapy. Given the FDA approval and widespread availability of 18F-fluciclovine, the findings could have impact in the immediate future in guiding initial management of patients with prostate cancer.
Study in Nature Medicine shows superior outcomes for patients in LLS's paradigm-shifting beat AML clinical trial.
This randomized clinical trial compared the change in pain severity among adults with chronic low back pain who received electroacupuncture or a placebo treatment.
A preliminary analysis of photon therapy treatment group 1 from the phase II NRG Oncology clinical trial NRG-BN001 indicates that there is no statistically significant overall survival (OS) or toxicity differences between dose-intensification radiation therapy (DI-RT) using intensity-modulated radiation therapy (IMRT) and standard-dose radiation therapy (SD-RT) with temozolomide treatments for patients with newly diagnosed glioblastoma (GBM).